Brain Hemorrhage – Pipeline Review, 2019

A brain hemorrhage refers to a medical condition where there is bleeding in the brain and is also alternatively referred to as intracranial hemorrhage or a brain bleed. A brain hemorrhage is a type of stroke, where an artery in the brain bursts and results in localized bleeding in the surrounding tissues. A brain hemorrhage is a life-threatening condition and it is critical to receive adequate medical attention immediately. Brain hemorrhages are common and account for 13% of all the strokes occurring.

Some of the factors contributing to the occurrence of brain hemorrhages include head injuries or trauma, brain aneurysm, brain tumor, high blood pressure, bleeding disorders or blood vessel abnormalities. Some of the symptoms of brain hemorrhage include severe and sudden headache, problems with vision, loss of balance and coordination, seizures, slurred speech and confusion or difficulties in understanding. Some of the diagnosis options for brain hemorrhages include CT scans, MRI, X-rays of the brain and lumbar puncture (spinal tap).

Pharmaceutical companies and various research institutes have been focusing on studying and developing new treatment options for brain hemorrhage. For instance; PG2, which is being studied by PhytoHealth Corporation, is currently in early phase-1 clinical trials for the pilot clinical study on hemorrhagic stroke.

At present more than 60% of the pipeline candidates for Brain Hemorrhage are in the phase-1 and phase-2 stage. Majority of the studies are sponsored by industry and government institutions.

Report Description

The report on ‘Brain Hemorrhage – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Brain Hemorrhage. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Brain Hemorrhage.

The report on ‘Brain Hemorrhage – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Brain Hemorrhage
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Brain Hemorrhage
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary